Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Abbott's Depacon

Executive Summary

Abbott's Depacon: Injectable formulation of valproate sodium is "approvable" as of June 6 for complex partial seizures and for simple and complex absence seizures. Related to Depakote (divalproex sodium) and Depakene (valproic acid), Depacon is also "approvable" as adjunct therapy for multiple seizure types. Abbott filed the Depacon NDA on March 20, 1995...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel